MedPage Today on MSN6d
First Omalizumab Biosimilar Approved
The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...
Medscape4d
Omalizumab vs Oral Immunotherapy: No Clear Winner
In the trials, omalizumab and multi-allergen oral immunotherapy showed alike efficacy in protecting against food allergies, ...
MedPage Today on MSN12d
Omalizumab Superior to Oral Immunotherapy for Kids With Multi-Food Allergy
Omalizumab (Xolair) injections outperformed oral immunotherapy (OIT) in increasing tolerance among children with multi-food ...
Rolling Out6d
New drug outperforms therapy for severe food allergies
Clinical trial shows omalizumab (Xolair) treats multiple severe food allergies more effectively than oral immunotherapy, with ...
Medical Xpress on MSN6d
Omalizumab treats multi-food allergy better than oral immunotherapy, unravels study
A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively ...
News Medical on MSN13d
Omalizumab outperforms oral immunotherapy in treating multi-food allergy
A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively ...
Injectable asthma drug resolves dangerous food allergies in one-third of children
More than a third of food-allergic kids were able to eat full servings of their trigger foods after treatment with an ...
MPR10d
Omalizumab vs OIT: Head-to-Head Study Compares Food Allergy Treatments
Omalizumab was found to be more effective than multi-allergen oral immunotherapy (OIT) in reducing allergic reactions in patients with 1 or more food allergies, according to results from Stage 2 of ...
Morningstar7d
U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimilar ...
European Medical Journal3d
Advances in Allergic Asthma Treatment: A Comparative Study
Discover a study that compared the effectiveness of P043 versus omalizumab in managing uncontrolled allergic asthma.
manilatimes7d
U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
JERSEY CITY, N.J., March 10, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO ® (omalizumab-igec) as the first and only biosimilar designated ...